• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含脒化合物中AMPA受体抑制机制的多样性。

The diversity of AMPA receptor inhibition mechanisms among amidine-containing compounds.

作者信息

Zhigulin Arseniy S, Dron Mikhail Y, Barygin Oleg I, Tikhonov Denis B

机构信息

Laboratory for the Research of the Mechanisms of Regulation and Compensation of Nervous System Excitability Pathologies, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry RAS, Saint Petersburg, Russia.

出版信息

Front Pharmacol. 2024 Oct 9;15:1467266. doi: 10.3389/fphar.2024.1467266. eCollection 2024.

DOI:10.3389/fphar.2024.1467266
PMID:39444609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11496081/
Abstract

Amidine-containing compounds are primarily known as antiprotozoal agents (pentamidine, diminazene, furamidine) or as serine protease inhibitors (nafamostat, sepimostat, camostat, gabexate). DAPI is widely recognized as a fluorescent DNA stain. Recently, it has been shown that these compounds also act as NMDA receptor inhibitors. In this study, we examined the activity of these compounds and analyzed the mechanisms of action in relation to another important class of ionotropic glutamate receptors-calcium-permeable AMPA receptors (CP-AMPARs) and calcium-impermeable AMPA receptors (CI-AMPARs) - using the whole-cell patch-clamp method on isolated male Wistar rat brain neurons. Gabexate and camostat were found to be inactive. Other compounds preferentially inhibited calcium-permeable AMPA receptors with IC values of 30-60 µM. DAPI and furamidine were also active against CI-AMPARs with ICs of 50-60 μM, while others showed poor activity. All active compounds acted as channel blockers, which are able for permeating into the cytoplasm on both CP- and CI-AMPARs. Specifically, sepimostat showed trapping in the closed CP-AMPAR channel. Furamidine and DAPI demonstrated a voltage-independent action on CI-AMPARs, indicating binding to an additional superficial site. While the majority of compounds inhibited glutamate-activated steady-state currents as well as kainate-activated currents on CI-AMPARs, pentamidine significantly potentiated glutamate-induced steady-state responses. The potentiating effect of pentamidine resembles the action of the positive allosteric modulator cyclothiazide although the exact binding site remains unclear. Thus, this study, together with our previous research on NMDA receptors, provides a comprehensive overview of this novel group of ionotropic glutamate receptors inhibitors with a complex pharmacological profile, remarkable diversity of effects and mechanisms of action.

摘要

含脒化合物主要作为抗原虫剂(喷他脒、二脒那秦、呋喃脒)或丝氨酸蛋白酶抑制剂(萘莫司他、司匹莫司他、卡莫司他、加贝酯)而为人所知。4',6-二脒基-2-苯基吲哚(DAPI)被广泛认为是一种荧光DNA染色剂。最近,已表明这些化合物还可作为N-甲基-D-天冬氨酸(NMDA)受体抑制剂。在本研究中,我们使用全细胞膜片钳方法,对分离的雄性Wistar大鼠脑神经元进行研究,检测了这些化合物的活性,并分析了其与另一类重要的离子型谷氨酸受体——钙通透型α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(CP-AMPARs)和钙不通透型α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(CI-AMPARs)相关的作用机制。发现加贝酯和卡莫司他无活性。其他化合物优先抑制钙通透型AMPA受体,其半数抑制浓度(IC)值为30 - 60微摩尔。DAPI和呋喃脒对CI-AMPARs也有活性,其IC值为50 - 60微摩尔,而其他化合物活性较差。所有活性化合物均作为通道阻滞剂,能够渗透到CP-AMPARs和CI-AMPARs的细胞质中。具体而言,司匹莫司他显示被困在关闭的CP-AMPAR通道中。呋喃脒和DAPI对CI-AMPARs表现出电压非依赖性作用,表明它们与另一个表面位点结合。虽然大多数化合物抑制CI-AMPARs上的谷氨酸激活的稳态电流以及海人藻酸激活的电流,但喷他脒显著增强了谷氨酸诱导的稳态反应。喷他脒的增强作用类似于正变构调节剂环噻嗪的作用,尽管确切的结合位点尚不清楚。因此,本研究与我们之前对NMDA受体的研究一起,对这组具有复杂药理特性、显著多样的效应和作用机制的新型离子型谷氨酸受体抑制剂提供了全面的概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/b8da80f288c4/fphar-15-1467266-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/2ee3d2ad6464/fphar-15-1467266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/2b2d983f6417/fphar-15-1467266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/bb7b0fed0138/fphar-15-1467266-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/0faf4915db57/fphar-15-1467266-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/17e079c8a4a0/fphar-15-1467266-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/108fda9f186f/fphar-15-1467266-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/b3bfe3b65134/fphar-15-1467266-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/6c3ae0c04337/fphar-15-1467266-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/b8da80f288c4/fphar-15-1467266-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/2ee3d2ad6464/fphar-15-1467266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/2b2d983f6417/fphar-15-1467266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/bb7b0fed0138/fphar-15-1467266-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/0faf4915db57/fphar-15-1467266-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/17e079c8a4a0/fphar-15-1467266-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/108fda9f186f/fphar-15-1467266-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/b3bfe3b65134/fphar-15-1467266-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/6c3ae0c04337/fphar-15-1467266-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff1/11496081/b8da80f288c4/fphar-15-1467266-g009.jpg

相似文献

1
The diversity of AMPA receptor inhibition mechanisms among amidine-containing compounds.含脒化合物中AMPA受体抑制机制的多样性。
Front Pharmacol. 2024 Oct 9;15:1467266. doi: 10.3389/fphar.2024.1467266. eCollection 2024.
2
Mechanisms of NMDA Receptor Inhibition by Sepimostat-Comparison with Nafamostat and Diarylamidine Compounds.西司他汀对 NMDA 受体抑制作用的机制研究——与那法司他汀和二芳基脒化合物的比较。
Int J Mol Sci. 2023 Oct 27;24(21):15685. doi: 10.3390/ijms242115685.
3
Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.那法莫司他、加贝酯和喷他脒抑制N-甲基-D-天冬氨酸受体的机制。
Eur J Pharmacol. 2022 Mar 15;919:174795. doi: 10.1016/j.ejphar.2022.174795. Epub 2022 Feb 3.
4
Screening for Activity Against AMPA Receptors Among Anticonvulsants-Focus on Phenytoin.抗惊厥药物中针对AMPA受体活性的筛选——以苯妥英为重点。
Front Pharmacol. 2021 Dec 7;12:775040. doi: 10.3389/fphar.2021.775040. eCollection 2021.
5
Mechanisms of acid-sensing ion channels inhibition by nafamostat, sepimostat and diminazene.那法莫司他、司匹莫司他和地美硝唑对酸敏感离子通道的抑制机制。
Eur J Pharmacol. 2023 Jan 5;938:175394. doi: 10.1016/j.ejphar.2022.175394. Epub 2022 Nov 17.
6
Mechanisms of AMPA Receptor Inhibition by Diminazene.二脒那嗪对AMPA受体的抑制机制
Neurosci Behav Physiol. 2022;52(2):308-314. doi: 10.1007/s11055-022-01238-y. Epub 2022 Mar 18.
7
Ca(2+)-permeable AMPA and NMDA receptor channels in basket cells of rat hippocampal dentate gyrus.大鼠海马齿状回篮状细胞中钙离子通透的AMPA和NMDA受体通道
J Physiol. 1995 Jun 1;485 ( Pt 2)(Pt 2):383-402. doi: 10.1113/jphysiol.1995.sp020737.
8
Mechanisms of NMDA receptor inhibition by diarylamidine compounds.二芳基脒类化合物抑制 NMDA 受体的机制。
Eur J Neurosci. 2020 Apr;51(7):1573-1582. doi: 10.1111/ejn.14589. Epub 2019 Nov 1.
9
Ca2+-permeable non-NMDA glutamate receptors in rat magnocellular basal forebrain neurones.大鼠大细胞基底前脑神经元中钙离子通透的非NMDA型谷氨酸受体
J Physiol. 1998 Apr 15;508 ( Pt 2)(Pt 2):453-69. doi: 10.1111/j.1469-7793.1998.453bq.x.
10
Functional characteristics of non-NMDA-type ionotropic glutamate receptor channels in AII amacrine cells in rat retina.大鼠视网膜AII无长突细胞中非NMDA型离子otropic谷氨酸受体通道的功能特性
J Physiol. 2002 Jul 1;542(Pt 1):147-65. doi: 10.1113/jphysiol.2002.020305.

本文引用的文献

1
Allosteric competition and inhibition in AMPA receptors.变构竞争和 AMPA 受体抑制。
Nat Struct Mol Biol. 2024 Nov;31(11):1669-1679. doi: 10.1038/s41594-024-01328-0. Epub 2024 Jun 4.
2
Mechanisms of NMDA Receptor Inhibition by Sepimostat-Comparison with Nafamostat and Diarylamidine Compounds.西司他汀对 NMDA 受体抑制作用的机制研究——与那法司他汀和二芳基脒化合物的比较。
Int J Mol Sci. 2023 Oct 27;24(21):15685. doi: 10.3390/ijms242115685.
3
Light-Sensitive Open Channel Block of Ionotropic Glutamate Receptors by Quaternary Ammonium Azobenzene Derivatives.
光敏感的季铵盐型偶氮苯衍生物对离子型谷氨酸受体的开放通道阻断作用。
Int J Mol Sci. 2023 Sep 7;24(18):13773. doi: 10.3390/ijms241813773.
4
Possible Compensatory Role of ASICs in Glutamatergic Synapses.ASICs 在谷氨酸能突触中的可能补偿作用。
Int J Mol Sci. 2023 Aug 19;24(16):12974. doi: 10.3390/ijms241612974.
5
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.在氯胺酮时代之后的抗抑郁药:靶向谷氨酸能系统的药理学方法。
Neuropharmacology. 2023 Feb 1;223:109348. doi: 10.1016/j.neuropharm.2022.109348. Epub 2022 Nov 21.
6
Mechanisms of acid-sensing ion channels inhibition by nafamostat, sepimostat and diminazene.那法莫司他、司匹莫司他和地美硝唑对酸敏感离子通道的抑制机制。
Eur J Pharmacol. 2023 Jan 5;938:175394. doi: 10.1016/j.ejphar.2022.175394. Epub 2022 Nov 17.
7
Dextromethorphan/Bupropion: First Approval.右美沙芬/安非他酮:首次批准。
CNS Drugs. 2022 Nov;36(11):1229-1238. doi: 10.1007/s40263-022-00968-4.
8
Mechanisms of AMPA Receptor Inhibition by Diminazene.二脒那嗪对AMPA受体的抑制机制
Neurosci Behav Physiol. 2022;52(2):308-314. doi: 10.1007/s11055-022-01238-y. Epub 2022 Mar 18.
9
Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.那法莫司他、加贝酯和喷他脒抑制N-甲基-D-天冬氨酸受体的机制。
Eur J Pharmacol. 2022 Mar 15;919:174795. doi: 10.1016/j.ejphar.2022.174795. Epub 2022 Feb 3.
10
Screening for Activity Against AMPA Receptors Among Anticonvulsants-Focus on Phenytoin.抗惊厥药物中针对AMPA受体活性的筛选——以苯妥英为重点。
Front Pharmacol. 2021 Dec 7;12:775040. doi: 10.3389/fphar.2021.775040. eCollection 2021.